Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02479308 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers
A Phase 1 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
NCT02479308: Completed Phase 1 study, sponsored by Alkermes.
NCT02479308 is a Phase 1 study that has completed, run by Alkermes. The registered enrollment target is 129 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (115% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02479308, a Phase 1 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
Study Summary
This study will evaluate the effects of ALKS 5461 on QT intervals in healthy volunteers as well as evaluate the safety and tolerability of ALKS 5461.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG ALKS 5461
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
What the finished NCT02479308 record still lists
NCT02479308 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (115% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02479308 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02479308 about?
NCT02479308 is a clinical study titled "A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers". This study will evaluate the effects of ALKS 5461 on QT intervals in healthy volunteers as well as evaluate the safety and tolerability of ALKS 5461.
What is the current status of trial NCT02479308?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2015-06. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02479308?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), ALKS 5461 (DRUG).
Who is sponsoring clinical trial NCT02479308?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02479308's enrollment target sits among peer trials
129 451st of 2000 higher than 1,549 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia